Rate and Predictors of Prescription of Lumacaftor – Ivacaftor in the 18 Months Following Approval in the United States
Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.
Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and ɣ improves cystic fibrosis-like disease in mice
